These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6035 related articles for article (PubMed ID: 3102397)

  • 21. Effect of inhibition of polyamine biosynthesis by DL-alpha-difluoromethylornithine on the growth and melanogenesis of B16 melanoma in vitro and in vivo.
    Sunkara PS; Chang CC; Prakash NJ; Lachmann PJ
    Cancer Res; 1985 Sep; 45(9):4067-70. PubMed ID: 3928149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potentiation of antitumor and antimetastatic activities of alpha-difluoromethylornithine by interferon inducers.
    Sunkara PS; Prakash NJ; Rosenberger AL; Hagan AC; Lachmann PJ; Mayer GD
    Cancer Res; 1984 Jul; 44(7):2799-802. PubMed ID: 6426786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimetastatic activity of DL-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, in mice.
    Sunkara PS; Rosenberger AL
    Cancer Res; 1987 Feb; 47(4):933-5. PubMed ID: 3100031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy with inhibitors of polyamine biosynthesis in refractory prostatic carcinoma. An experimental and clinical study].
    Dunzendorfer U; Knöner M
    Onkologie; 1985 Aug; 8(4):196-200. PubMed ID: 2419811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastasis of hormone-independent breast cancer to lung and bone is decreased by alpha-difluoromethylornithine treatment.
    Richert MM; Phadke PA; Matters G; DiGirolamo DJ; Washington S; Demers LM; Bond JS; Manni A; Welch DR
    Breast Cancer Res; 2005; 7(5):R819-27. PubMed ID: 16168128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The enzyme-activated irreversible inhibitor of ornithine decarboxylase, DL-alpha-difluoromethylornithine: a chemopreventive agent.
    Verma AK
    Prev Med; 1989 Sep; 18(5):646-52. PubMed ID: 2515533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells.
    Ignatenko NA; Zhang H; Watts GS; Skovan BA; Stringer DE; Gerner EW
    Mol Carcinog; 2004 Apr; 39(4):221-33. PubMed ID: 15057874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of lupus nephritis in MRL-lpr/lpr mice by inhibiting ornithine decarboxylase.
    Gunnia UB; Amenta PS; Seibold JR; Thomas TJ
    Kidney Int; 1991 May; 39(5):882-90. PubMed ID: 2067204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I evaluation of intravenous difluoromethylornithine--a polyamine inhibitor.
    Maddox AM; Keating MJ; McCredie KE; Estey E; Freireich EJ
    Invest New Drugs; 1985; 3(3):287-92. PubMed ID: 3934106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
    Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
    Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of hepatic arterial infusion using difluoromethylornithine.
    Lipton A; Harvey HA; Glenn J; Weidner WA; Strauss M; Miller SE; Taylor JB; White-Hershey D; Barlow JL
    Cancer; 1989 Feb; 63(3):433-7. PubMed ID: 2492203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.
    Qu N; Ignatenko NA; Yamauchi P; Stringer DE; Levenson C; Shannon P; Perrin S; Gerner EW
    Biochem J; 2003 Oct; 375(Pt 2):465-70. PubMed ID: 12859253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.
    Love RR; Jacoby R; Newton MA; Tutsch KD; Simon K; Pomplun M; Verma AK
    Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):989-92. PubMed ID: 9829706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells.
    Matters GL; Manni A; Bond JS
    Clin Exp Metastasis; 2005; 22(4):331-9. PubMed ID: 16170669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
    Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
    Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. alpha-difluoromethylornithine induces apoptosis as well as anti-angiogenesis in the inhibition of tumor growth and metastasis in a human gastric cancer model.
    Takahashi Y; Mai M; Nishioka K
    Int J Cancer; 2000 Jan; 85(2):243-7. PubMed ID: 10629084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
    Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
    Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of alpha-difluoromethylornithine and recombinant interferon-alpha 2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice.
    Heston WD; Fleischmann J; Tackett RE; Ratliff TL
    Cancer Res; 1984 Aug; 44(8):3220-5. PubMed ID: 6430546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
    Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
    Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
    Einspahr JG; Nelson MA; Saboda K; Warneke J; Bowden GT; Alberts DS
    Clin Cancer Res; 2002 Jan; 8(1):149-55. PubMed ID: 11801552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 302.